Clinical Trial Detail

NCT ID NCT03846310
Title A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Arcus Biosciences, Inc.
Indications

lung non-small cell carcinoma

Therapies

AB928 + Carboplatin + Pemetrexed Disodium

GLS-010

AB928 + Carboplatin + Pembrolizumab + Pemetrexed Disodium

Age Groups: senior adult

No variant requirements are available.